Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00529841|
Recruitment Status : Completed
First Posted : September 14, 2007
Last Update Posted : September 14, 2015
The purpose of this study is to develop a more physiological approach to the management of children and adolescents with salt wasting Congenital Adrenal Hyperplasia.
We will administer the glucocorticosteroid via insulin infusion pump to see whether this treatment will improve the serum hormone concentrations.
|Condition or disease||Intervention/treatment||Phase|
|Adrenal Hyperplasia, Congenital||Drug: Hydrocortisone sodium acetate||Not Applicable|
The adrenal gland is a small organ of the body. It produces very important chemicals called hormones. One of these hormones, cortisol (the stress hormone) helps the body fight diseases. The other hormone is the aldosterone helps to maintain the normal amount of salt and water in the body. The third type of hormones are the androgens or male hormones, which cause some of the changes during puberty, like the growth of body hair and pimples.
The salt wasting Congenital Adrenal Hyperplasia or CAH disease is a disease of the adrenal gland. Patients with this disease cannot make cortisol or the aldosterone. As a result, their body cannot fight diseases and cannot keep normal amounts of salt and water in the body. At the same time, the gland makes too much of the male hormones, which is bad for the body because too much male hormone slows down growth, increases the growth of body hair, and causes pimples and abnormal period in girls.
Patients with this disease have to take medications every day. However, the treatment does not work very well, because usually the patients do not have the right amount of hormone in their body. Usually the body gets too much hormone right after taking the pills. A couple of hours later the body has too little of the hormones, because in the meantime the body gets rid of the medication.The healthy adrenal gland makes the hormones throughout the day in different amounts. The patients with this disease take the medication only a couple of times a day. They take the Florinef tablet once a day and the Cortisol tablet two or three times a day. The treatment that we use today by mouth cannot copy the natural hormone productions of the adrenal gland. Because of this it does not make much of a difference in the patient's life.
We would like to improve the treatment and find out the effect of a new treatment. In this study we will try to imitate the body's normal hormone production and will give the medication via an insulin pump to see if this treatment method will decrease the male hormones in the blood. This study will help us to develop a new and better treatment for children and adolescents.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia|
|Study Start Date :||January 2007|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2008|
Experimental: 1 (Hydrocortisone sodium acetate)
Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
Drug: Hydrocortisone sodium acetate
Subcutaneous administration of medication via insulin pump
Other Name: Solu-Cortef injection
- Serum 17-OHP concentration in the morning [ Time Frame: 11 days ]
- serum steroid hormone profiles [ Time Frame: 11 days ]
- serum blood glucose [ Time Frame: study days 2,3 and 11 ]
- serum sodium [ Time Frame: study days 2,3 and 11 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00529841
|United States, Texas|
|BCM, Texas Children's Hospital Clinic and General Clinical Research Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Morey W Haymond, MD||Baylor College of Medicine|